Delia Salaru

TL;DR: A comprehensive overview on midkine and its functions in atherogenesis and kidney diseases is provided, including molecular clues to key signalling pathways (Akt, ERK, HIF1α) and key events in atherosclerotic vessels link midKine expression with vascular smooth muscle proliferation and (neo)angiogenesis.

TL;DR: Both visit-to-visit systolic BPV and aortic stiffness proved to be positively and independently correlated with the risk category and together might contribute to the improvement of cardiovascular risk prediction models.

TL;DR: The high levels of midkine in severe peripheral artery disease patients introduce this cytokine as a possible novel effector in the advanced atherosclerotic process, and suggest a functional link between vascular receptor autoantibody formation and down-regulated midKine serum levels, that may be relevant in the pathogenesis of clinically relevant peripheral artery occlusive disease.

TL;DR: Cell-specific receptor Notch3 signaling independently orchestrates leukocyte infiltration and organ fibrosis and may present a novel therapeutic approach in inflammatory as well as fibrotic diseases.

TL;DR: The evolution of technological processes in medicine has shifted the attention of researchers from the profiling of classical risk factors to the identification of new biomarkers such as midregional pro-adrenomedullin, midkine, stromelysin-2, pentraxin 3, inflammasomes, or endothelial cell-derived extracellular vesicles, which are seen as future therapeutic targets associated with decreased morbidity and mortality through early diagnosis of atherosclerotic lesions.